Eplerenone for the Treatment of Central Serous Chorioretinopathy
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2018
Price : $35 *
At a glance
- Drugs Eplerenone (Primary)
- Indications Central serous chorioretinopathy
- Focus Therapeutic Use
- Acronyms ECSelsior
- 09 Jan 2017 Status changed from active, no longer recruiting to completed.
- 19 Feb 2015 Planned End Date changed from 1 Oct 2014 to 1 May 2015 as per ClinicalTrials.gov record.
- 19 Feb 2015 Planned primary completion date changed from 1 Oct 2014 to 1 Mar 2015 as per ClinicalTrials.gov record.